Overview

Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome

Status:
Recruiting
Trial end date:
2023-06-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to study the effectiveness of implementation of a systematic LDL-C management pathway including treatment with inclisiran in participants who have experienced a recent acute coronary syndrome (ACS) and have an increased LDL-cholesterol (≥70 mg/dL) despite being treated with a statin drug,
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals